These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8886295)

  • 41. Abnormalities in event-related potentials: N100, N200 and P300 topography in alcoholics.
    Miyazato Y; Ogura C
    Jpn J Psychiatry Neurol; 1993 Dec; 47(4):853-62. PubMed ID: 8201796
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Depression predicts higher rates of heroin use on desipramine with buprenorphine than with methadone.
    Kosten T; Falcioni J; Oliveto A; Feingold A
    Am J Addict; 2004; 13(2):191-201. PubMed ID: 15204669
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interactive ERP recording increases the amplitude of the endogenous P300 peak in schizophrenia.
    Price GW
    Schizophr Res; 2000 Feb; 41(3):463-72. PubMed ID: 10728723
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Pharmacological treatment of substance dependence from a neuroscientific perspective (I): opiates and cocaine].
    Haro G; Cervera G; Martínez-Raga J; Pérez-Gálvez B; Fernández-Garcés M; Sanjuan J
    Actas Esp Psiquiatr; 2003; 31(4):205-19. PubMed ID: 12838444
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Thrice-weekly versus daily buprenorphine maintenance.
    Schottenfeld RS; Pakes J; O'Connor P; Chawarski M; Oliveto A; Kosten TR
    Biol Psychiatry; 2000 Jun; 47(12):1072-9. PubMed ID: 10862807
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone.
    Seifert J; Metzner C; Paetzold W; Borsutzky M; Ohlmeier M; Passie T; Hauser U; Becker H; Wiese B; Emrich H; Schneider U
    Addict Biol; 2005 Jun; 10(2):157-64. PubMed ID: 16191668
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Buprenorphine as a new alternative for detoxification of heroin addicts. It causes only mild withdrawal problems, abating quickly].
    Blennow G; Fergusson A; Medvedeo A
    Lakartidningen; 2000 Apr; 97(15):1830-3. PubMed ID: 10815411
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Maintenance for opioid addiction with buprenorphine and methadone: "The only thing new in the world is the history you don't know".
    Stimmel B
    J Addict Dis; 2005; 24(3):1-6. PubMed ID: 16186079
    [No Abstract]   [Full Text] [Related]  

  • 49. Improved regional cerebral blood flow in chronic cocaine polydrug users treated with buprenorphine.
    Levin JM; Mendelson JH; Holman BL; Teoh SK; Garada B; Schwartz RB; Mello NK
    J Nucl Med; 1995 Jul; 36(7):1211-5. PubMed ID: 7790946
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transitioning opioid-dependent patients from detoxification to long-term treatment: efficacy of intensive role induction.
    Katz EC; Brown BS; Schwartz RP; O'Grady KE; King SD; Gandhi D
    Drug Alcohol Depend; 2011 Aug; 117(1):24-30. PubMed ID: 21277704
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined buprenorphine and chlonidine for short-term opiate detoxification: patient perspectives.
    Wallen MC; Lorman WJ; Gosciniak JL
    J Addict Dis; 2006; 25(1):23-31. PubMed ID: 16597570
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of differential doses of buprenorphine for long term pharmacotherapy among opiate dependent subjects.
    De S; Jain R; Ray R; Dhawan A; Varghese ST
    Indian J Physiol Pharmacol; 2008; 52(1):53-63. PubMed ID: 18831352
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Consensus statement on office-based treatment of opioid dependence using buprenorphine.
    Fiellin DA; Kleber H; Trumble-Hejduk JG; McLellan AT; Kosten TR
    J Subst Abuse Treat; 2004 Sep; 27(2):153-9. PubMed ID: 15450648
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Buprenorphine-naloxone treatment responses differ between young adults with heroin and prescription opioid use disorders.
    Romero-Gonzalez M; Shahanaghi A; DiGirolamo GJ; Gonzalez G
    Am J Addict; 2017 Dec; 26(8):838-844. PubMed ID: 29143399
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Buprenorphine in opiate withdrawal: a comparison with clonidine.
    Nigam AK; Ray R; Tripathi BM
    J Subst Abuse Treat; 1993; 10(4):391-4. PubMed ID: 8257551
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparing buprenorphine induction experience with heroin and prescription opioid users.
    Nielsen S; Hillhouse M; Mooney L; Fahey J; Ling W
    J Subst Abuse Treat; 2012 Oct; 43(3):285-90. PubMed ID: 22301084
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A cost-effectiveness analysis of buprenorphine-assisted heroin withdrawal.
    Doran CM; Shanahan M; Bell J; Gibson A
    Drug Alcohol Rev; 2004 Jun; 23(2):171-5. PubMed ID: 15370023
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of buprenorphine in the management of heroin addiction.
    Sung S; Conry JM
    Ann Pharmacother; 2006 Mar; 40(3):501-5. PubMed ID: 16434562
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of cocaine on P3B in cocaine abusers.
    Herning RI; Glover BJ; Guo X
    Neuropsychobiology; 1994; 30(2-3):132-42. PubMed ID: 7800160
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Less pain, more gain: buprenorphine-naloxone and patient retention in treatment.
    Renzelli CM; Capretto NA
    J Addict Dis; 2006; 25(3):97-104. PubMed ID: 16956874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.